Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral (AAV) vector gene therapy has shown promise as a possible cure for hemophilia. However, immune responses directed against AAV vectors remain a hurdle to the broader use of this gene transfer platform. Both innate and adaptive immune responses can affect the safety and efficacy of AAV vector–mediated gene transfer in humans. These immune responses may be triggered by the viral capsid, the vector’s nucleic acid payload, or other vector contaminants or excipients, or by the transgene product encoded by the vector itself. Various preclinical and clinical strategies have been explored to overcome the issues of AAV vector immunogenicity and transgene-related immune responses. Although results of these strategies are encouraging, more efficient approaches are needed to deliver safe, predictable, and durable outcomes for people with hemophilia. In addition to durability, long-term follow-up of gene therapy trial participants will allow us to address potential safety concerns related to vector integration. Herein, we describe the challenges with current methodologies to deliver optimal outcomes for people with hemophilia who choose to undergo AAV vector gene therapy and the potential opportunities to improve on the results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 5×
“Although some trials showed that a short course of oral corticosteroids blocked an apparent capsid-driven T-cell response [10,11,20], this approach has not always been successful [4], even when high-dose corticosteroids were used [5,21].”
BackgroundMethodResultInfluentialSelf-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationEngineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 5×
“, to achieve equivalent or better transgene expression with exposure to lower vector doses) [98].”
BackgroundMethodInfluentialClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · cited 7×
“However, the deoxyribonucleic acid (DNA) component of the AAV vector and the double-stranded ribonucleic acid (dsRNA) produced by the vector may also contribute to activation of the innate response [4,48,49].”
BackgroundInfluentialHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 7×
“Similar to the case with NAbs, there is evidence for cross-reactivity in cytotoxic T-lymphocyte (CTL) responses across multiple AAV serotypes [4,16,71].”
BackgroundResultInfluentialSelf-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735 · cited 2×
“Modification of the AAV inverted terminal repeats (ITRs) to generate self-complementary (sc) AAVs has been used to increase expression upon transduction and allow transgene expression without the need for single-stranded (ss) DNA synthesis [98,103].”
BackgroundSelf-citationAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694 · cited 1×
“No inhibitor development, thromboses, or deaths were observed, although changes in liver function tests lasting several weeks were documented; furthermore, the long-term impact of transgene expression has yet to be determined [8,46].”
BackgroundAAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas
Nault, J.-C., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, E., Pilati, C., Verret, B., Blanc, J.-F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3389 · Cited by 489
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Self-citationSelection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450 · cited 1×
“Strategies under evaluation in preclinical models and clinical trials include maximizing vector potency to decrease the therapeutic dose and the risk of immune-mediated toxicity, as well as increasing target cell transduction efficiency [96,97], transgene expression levels [44], or transgene activity [11,43].”
BackgroundIntegration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908490 · Cited by 448
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394 · cited 3×
“FIX Padua is a naturally occurring missense variant (FIX R338L) with an 8-fold higher FIX-specific activity compared to wild-type (WT) FIX [14,23].”
BackgroundMethodImmune tolerance: What is unique about the liver
Tiegs, G., & Lohse, A. W. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.08.008 · Cited by 394
IgG endopeptidase in highly sensitized patients undergoing transplantation
Jordan, S. C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., Zhang, X., Eich, T., Toyoda, M., Eriksson, B.-M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612567 · Cited by 377
Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design
Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019) · Science · doi:10.1126/science.aaw2900 · Cited by 356 · cited 1×
“Strategies under evaluation in preclinical models and clinical trials include maximizing vector potency to decrease the therapeutic dose and the risk of immune-mediated toxicity, as well as increasing target cell transduction efficiency [96,97], transgene expression levels [44], or transgene activity [11,43].”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
Self-citationAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“As discussed above, the prevalence of NAbs to AAV vary with age of the individual, which may be important in the choice of the AAV serotype for clinical use in different populations (neonatal, pediatric, or adult) [4,28,84].”
BackgroundNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationA critical analysis of codon optimization in human therapeutics
Mauro, V. P., & Chappell, S. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.09.003 · Cited by 343
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
Self-citationZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 1×
“In nonparenchymal liver cells, such as Kupffer cells and liver sinusoidal endothelial cells (LSECs), the viral capsid activates innate immunity by binding to the Toll-like receptor (TLR) 2 [50], while the double-stranded (ds) DNA vector genome and unmethylated CpG motifs are recognized by TLR9 found in Kupffer cells […”
BackgroundJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 2×
“Preexisting NAbs to AAV can have an important impact on the efficacy of gene transfer [12,67].”
BackgroundSelf-citationGene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278 · cited 1×
“Strategies under evaluation in preclinical models and clinical trials include maximizing vector potency to decrease the therapeutic dose and the risk of immune-mediated toxicity, as well as increasing target cell transduction efficiency [96,97], transgene expression levels [44], or transgene activity [11,43].”
BackgroundSelf-citationMeliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 6×
“However, the deoxyribonucleic acid (DNA) component of the AAV vector and the double-stranded ribonucleic acid (dsRNA) produced by the vector may also contribute to activation of the innate response [4,48,49].”
BackgroundInfluentialSelf-citationMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., & Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-02-073304 · Cited by 220
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219 · cited 3×
“For example, it is known that TLR2 recognizes the AAV capsid peptides [50].”
BackgroundGeorge, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
Self-citationOvercoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212 · cited 2×
“Early clinical trial data support the role of innate immunity in AAV immunogenicity [5,30,82].”
BackgroundWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212 · cited 1×
“Given that NAb titers as low as 1:5 can completely block transduction of liver cells [47,83], the presence of antibodies to AAV is a common exclusion criterion in most liver-directed gene transfer trials.”
BackgroundTse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Self-citationKonkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189 · cited 9×
“Although some trials showed that a short course of oral corticosteroids blocked an apparent capsid-driven T-cell response [10,11,20], this approach has not always been successful [4], even when high-dose corticosteroids were used [5,21].”
BackgroundResultInfluentialSelf-citationKruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
Adeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178
Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177
Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288001 · Cited by 157
Crudele, J. M., Finn, J. D., Siner, J. I., Martin, N. B., Niemeyer, G. P., Zhou, S., Mingozzi, F., Lothrop, C. D., & Arruda, V. R. (2015) · Blood · doi:10.1182/blood-2014-07-588194 · Cited by 153
Self-citationWu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153 · cited 1×
“In some experimental models, FIX encoded by scAAV vectors is expressed earlier and at a higher level than when it is encoded by conventional ssAAV vectors [98,103,104].”
BackgroundSelf-citationNathwani, A. C. (2019) · Hematology · doi:10.1182/hematology.2019000007 · Cited by 140
Mingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Self-citationRescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M., & Asokan, A. (2020) · JCI Insight · doi:10.1172/jci.insight.139881 · Cited by 137
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135
Self-citationRogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131 · cited 2×
“In nonparenchymal liver cells, such as Kupffer cells and liver sinusoidal endothelial cells (LSECs), the viral capsid activates innate immunity by binding to the Toll-like receptor (TLR) 2 [50], while the double-stranded (ds) DNA vector genome and unmethylated CpG motifs are recognized by TLR9 found in Kupffer cells […”
BackgroundFields, P. A., Arruda, V. R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J. N., Herzog, R. W., & High, K. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0441 · Cited by 127 · cited 2×
“In mouse and dog models of hemophilia, the nature of host mutations in the F8 and F9 genes is a major determinant of the risk of inhibitor development in hemophilia gene transfer [51,126].”
BackgroundSelf-citationLind, P., Larsson, K., Spira, J., Sydow‐Báckman, M., Almstedt, A., Gray, E., & Sandberg, H. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20776.x · Cited by 120 · cited 1×
“AAV, adeno-associated virus; FVIII, factor VIII; NA, not applicable; FVIII-SQ, B domain-deleted FVIII gene with SQ linker at site of deleted B domain sequence [41]; UCL, University College of London.”
MethodShao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119 · cited 1×
“It has been suggested that rAAV transduction could lead to formation of double-stranded RNA intermediates in the cytosol, which could stimulate innate immune signaling through cytosolic RNA sensors [76].”
BackgroundMen with severe hemophilia in the United States: birth cohort analysis of a large national database
Mazepa, M. A., Monahan, P. E., Baker, J. R., Riske, B. K., & Soucie, J. M. (2016) · Blood · doi:10.1182/blood-2015-10-675140 · Cited by 117 · cited 1×
“Prior to the 1990s, most adults and teens with hemophilia who received transfusions of plasma-derived clotting factor concentrates developed hepatitis infections [53,54].”
BackgroundSelf-citationEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
Monahan, P. E., Sun, J., Gui, T., Hu, G., Hannah, W. B., Wichlan, D. G., Wu, Z., Grieger, J. C., Li, C., Suwanmanee, T., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.106 · Cited by 108
Self-citationExposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104 · cited 9×
“Thus, NAbs remain an impediment to more widespread use of AAV gene therapy, as well as restrict the ability to re-administer the vector, if needed [4,28].”
BackgroundResultInfluentialSelf-citationStrategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
Capsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Self-citationVeron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88 · cited 13×
“Unmethylated CpG motifs are uncommon in mammalian DNA but common in microbial DNA and may induce innate host defenses.”
BackgroundInfluentialRogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84
Self-citationShirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Alexaki, A., Hettiarachchi, G. K., Athey, J. C., Katneni, U. K., Simhadri, V., Hamasaki-Katagiri, N., Nanavaty, P., Lin, B., Takeda, K., Freedberg, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51984-2 · Cited by 78
Orlowski, A., Katz, M. G., Gubara, S. M., Fargnoli, A. S., Fish, K. M., & Weber, T. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.004 · Cited by 74
Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-122 · Cited by 69
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Self-citationQuantification of CpG motifs in rAAV genomes: Avoiding the toll
Wright, J. F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.006 · Cited by 65
Salas, D., Kwikkers, K. L., Zabaleta, N., Bazo, A., Petry, H., van Deventer, S. J., Aseguinolaza, G. G., & Ferreira, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000380 · Cited by 59
Nathwani, A. C., Tuddenham, E., Chowdary, P., McIntosh, J., Lee, D., Rosales, C., Phillips, M., Pie, J., Junfang, Z., Meagher, M. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118256 · Cited by 52
Samelson-Jones, B. J., Finn, J. D., Favaro, P., Wright, J. F., & Arruda, V. R. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.001 · Cited by 50 · cited 2×
“This study highlighted the importance of regulatory T-cells (Tregs) as mediators of transgene immune tolerance following hepatic gene transfer [92] and showed how drugs interfering with Treg induction could trigger a detrimental anti-transgene immune response [49,93,94].”
BackgroundHyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
Samelson-Jones, B. J., Finn, J. D., George, L. A., Camire, R. M., & Arruda, V. R. (2019) · JCI Insight · doi:10.1172/jci.insight.128683 · Cited by 44
Herzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
Denard, J., Marolleau, B., Jenny, C., Rao, T. N., Fehling, H. J., Voit, T., & Svinartchouk, F. (2013) · Journal of Virology · doi:10.1128/jvi.01813-13 · Cited by 31
Vandamme, C., Xicluna, R., Hesnard, L., Devaux, M., Jaulin, N., Guilbaud, M., Le Duff, J., Couzinié, C., Moullier, P., Saulquin, X., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03110 · Cited by 23
Cited by
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
“Despite their potential for the delivery and expression of miRNAs, there are various side effects with the use of viral vectors such as immunogenicity and transgene-related immune responses [233].”
BackgroundPrasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans
Kuoch, H., Krotova, K., Graham, M. L., Brantly, M. L., & Aslanidi, G. (2023) · Biomedicines · doi:10.3390/biomedicines11020523 · Cited by 5
Metadata
- Authors
- Monahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-02
- Volume
- 10
- Issue
- 11
- Pages
- 2471
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W3171241404
- Cited by
- 85
- References
- 82
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.